Muscle pain associated with daptomycin

Shailaja R. Veligandla, Kathy R. Louie, Mark A. Malesker, Philip W. Smith

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of muscle pain without pronounced creatine kinase (CK) elevation in a patient receiving daptomycin. CASE SUMMARY: A 26-year-old African American woman had antibiotic intolerance to vancomycin and quinupristin/dalfopristin. She presented with methicillin-resistant Staphylococcus aureus endocarditis that was treated with intravenous daptomycin 6 mg/kg daily for 14 days. The patient developed muscle aches and pains with only a minor elevation (492 U/L) of CK; both resolved after daptomycin was discontinued. DISCUSSION: Daptomycin is a newly approved lipopeptide antibiotic derived from Streptomyces roseosporus with rapid bactericidal activity. Daptomycin has excellent coverage against gram-positive bacteria. The adverse effect profile has included rare reports of myopathy and elevated CK levels. Daptomycin is a promising agent with many potential applications. Once-daily dosing has diminished the preclinical incidence of myopathy. The current package labeling recommends discontinuation of daptomycin with significant myopathy symptoms in association with a CK elevation >1000 U/L or in patients without muscle pain and a CK >10 times normal. CONCLUSIONS: An objective causality assessment revealed that the myopathy was possibly related to daptomycin. Clinicians should recognize that significant myopathy with daptomycin can occur without pronounced CK elevation.

Original languageEnglish
Pages (from-to)1860-1862
Number of pages3
JournalAnnals of Pharmacotherapy
Volume38
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Daptomycin
Myalgia
Creatine Kinase
Muscular Diseases
Anti-Bacterial Agents
Lipopeptides
faropenem medoxomil
Streptomyces
Gram-Positive Bacteria
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Endocarditis
Causality
African Americans
Pain

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Veligandla, S. R., Louie, K. R., Malesker, M. A., & Smith, P. W. (2004). Muscle pain associated with daptomycin. Annals of Pharmacotherapy, 38(11), 1860-1862. https://doi.org/10.1345/aph.1D639

Muscle pain associated with daptomycin. / Veligandla, Shailaja R.; Louie, Kathy R.; Malesker, Mark A.; Smith, Philip W.

In: Annals of Pharmacotherapy, Vol. 38, No. 11, 11.2004, p. 1860-1862.

Research output: Contribution to journalArticle

Veligandla, SR, Louie, KR, Malesker, MA & Smith, PW 2004, 'Muscle pain associated with daptomycin', Annals of Pharmacotherapy, vol. 38, no. 11, pp. 1860-1862. https://doi.org/10.1345/aph.1D639
Veligandla, Shailaja R. ; Louie, Kathy R. ; Malesker, Mark A. ; Smith, Philip W. / Muscle pain associated with daptomycin. In: Annals of Pharmacotherapy. 2004 ; Vol. 38, No. 11. pp. 1860-1862.
@article{02f9dab939564ad8b52de67d0693c422,
title = "Muscle pain associated with daptomycin",
abstract = "OBJECTIVE: To report a case of muscle pain without pronounced creatine kinase (CK) elevation in a patient receiving daptomycin. CASE SUMMARY: A 26-year-old African American woman had antibiotic intolerance to vancomycin and quinupristin/dalfopristin. She presented with methicillin-resistant Staphylococcus aureus endocarditis that was treated with intravenous daptomycin 6 mg/kg daily for 14 days. The patient developed muscle aches and pains with only a minor elevation (492 U/L) of CK; both resolved after daptomycin was discontinued. DISCUSSION: Daptomycin is a newly approved lipopeptide antibiotic derived from Streptomyces roseosporus with rapid bactericidal activity. Daptomycin has excellent coverage against gram-positive bacteria. The adverse effect profile has included rare reports of myopathy and elevated CK levels. Daptomycin is a promising agent with many potential applications. Once-daily dosing has diminished the preclinical incidence of myopathy. The current package labeling recommends discontinuation of daptomycin with significant myopathy symptoms in association with a CK elevation >1000 U/L or in patients without muscle pain and a CK >10 times normal. CONCLUSIONS: An objective causality assessment revealed that the myopathy was possibly related to daptomycin. Clinicians should recognize that significant myopathy with daptomycin can occur without pronounced CK elevation.",
author = "Veligandla, {Shailaja R.} and Louie, {Kathy R.} and Malesker, {Mark A.} and Smith, {Philip W.}",
year = "2004",
month = "11",
doi = "10.1345/aph.1D639",
language = "English",
volume = "38",
pages = "1860--1862",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "11",

}

TY - JOUR

T1 - Muscle pain associated with daptomycin

AU - Veligandla, Shailaja R.

AU - Louie, Kathy R.

AU - Malesker, Mark A.

AU - Smith, Philip W.

PY - 2004/11

Y1 - 2004/11

N2 - OBJECTIVE: To report a case of muscle pain without pronounced creatine kinase (CK) elevation in a patient receiving daptomycin. CASE SUMMARY: A 26-year-old African American woman had antibiotic intolerance to vancomycin and quinupristin/dalfopristin. She presented with methicillin-resistant Staphylococcus aureus endocarditis that was treated with intravenous daptomycin 6 mg/kg daily for 14 days. The patient developed muscle aches and pains with only a minor elevation (492 U/L) of CK; both resolved after daptomycin was discontinued. DISCUSSION: Daptomycin is a newly approved lipopeptide antibiotic derived from Streptomyces roseosporus with rapid bactericidal activity. Daptomycin has excellent coverage against gram-positive bacteria. The adverse effect profile has included rare reports of myopathy and elevated CK levels. Daptomycin is a promising agent with many potential applications. Once-daily dosing has diminished the preclinical incidence of myopathy. The current package labeling recommends discontinuation of daptomycin with significant myopathy symptoms in association with a CK elevation >1000 U/L or in patients without muscle pain and a CK >10 times normal. CONCLUSIONS: An objective causality assessment revealed that the myopathy was possibly related to daptomycin. Clinicians should recognize that significant myopathy with daptomycin can occur without pronounced CK elevation.

AB - OBJECTIVE: To report a case of muscle pain without pronounced creatine kinase (CK) elevation in a patient receiving daptomycin. CASE SUMMARY: A 26-year-old African American woman had antibiotic intolerance to vancomycin and quinupristin/dalfopristin. She presented with methicillin-resistant Staphylococcus aureus endocarditis that was treated with intravenous daptomycin 6 mg/kg daily for 14 days. The patient developed muscle aches and pains with only a minor elevation (492 U/L) of CK; both resolved after daptomycin was discontinued. DISCUSSION: Daptomycin is a newly approved lipopeptide antibiotic derived from Streptomyces roseosporus with rapid bactericidal activity. Daptomycin has excellent coverage against gram-positive bacteria. The adverse effect profile has included rare reports of myopathy and elevated CK levels. Daptomycin is a promising agent with many potential applications. Once-daily dosing has diminished the preclinical incidence of myopathy. The current package labeling recommends discontinuation of daptomycin with significant myopathy symptoms in association with a CK elevation >1000 U/L or in patients without muscle pain and a CK >10 times normal. CONCLUSIONS: An objective causality assessment revealed that the myopathy was possibly related to daptomycin. Clinicians should recognize that significant myopathy with daptomycin can occur without pronounced CK elevation.

UR - http://www.scopus.com/inward/record.url?scp=7044223098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044223098&partnerID=8YFLogxK

U2 - 10.1345/aph.1D639

DO - 10.1345/aph.1D639

M3 - Article

C2 - 15367725

AN - SCOPUS:7044223098

VL - 38

SP - 1860

EP - 1862

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 11

ER -